Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans

The mitogen-activated protein kinase (MEK) inhibitor zapnometinib is in development to treat acute viral infections like COVID-19 and influenza. While the antiviral efficacy of zapnometinib is well documented, further data on target engagement/pharmacodynamics (PD) and pharmacokinetics (PK) are need...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Julia Koch-Heier, Annika Schönsiegel, Lara Maria Waidele, Julian Volk, Yvonne Füll, Christian Wallasch, Sebastian Canisius, Michael Burnet, Oliver Planz
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-06-01
coleção:	Frontiers in Pharmacology
Assuntos:	MEK inhibitor pharmacokinetic pharmacodynamic antiviral therapy zapnometinib WES
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2022.893635/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!